Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients

Exclusion Criteria

• •Participation in another clinical study with an investigational product during the last 30 days.
• •History of ACS within the last 1 year.
• •Hypersensitivity or contraindications to clopidogrel or ticagrelor.
• •Need for chronic oral anticoagulant therapy or chronic low- molecular-weight heparin or long-term treatment with fondaparinux, warfarin, apixaban, rivoroxaban, and parenteral anticoagulants such as enoxeparin, and bivalirudin.
• •Life expectancy \< 6 months based on investigator's judgment.
• •Planned lower extremity revascularization (surgical or endovascular) in any vascular territory within the next 3 months or with current ischemic ulcers or gangrene.
• •Planned major amputation due to PAD within the next 3 months or major amputation due to PAD within the last 30 days.
• •Subjects who have suffered a stroke during the past 3 months.
• •Dementia likely to jeopardize understanding of information pertinent to study conduct or compliance to study procedures
• •Severe hypertension that may put the subject at risk.
• •Subjects considered to be at risk of bradycardic events (e.g., known sick sinus syndrome or second or third degree AV block unless already treated with a permanent pacemaker.
• •Known severe liver disease (e.g., ascites and/or clinical signs of coagulopathy).
• •Renal failure requiring dialysis
• •A known bleeding diathesis, haemostatic or coagulation disorder, or systemic bleeding, whether resolved or ongoing
• •History of previous intracranial bleed at any time, gastrointestinal bleed within the past 6 months, or major surgery within 30 days (if the surgical wound is judged to be associated with an increased risk of bleeding).
• •History of thrombocytopenia or neutropenia
• •Females of child-bearing potential (i.e., those who are not chemically or surgically sterilized, post-menopausal who are not willing to use an accepted method of treatment OR who have a positive pregnancy test at screening.
• •Concern for inability of the subject to comply with study procedures and/or follow-up (e.g., alcohol or drug abuse).